Related Experiment Video
Updated: Dec 29, 2025
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Reduced Plasma NT-proBNP Levels Months after Myocardial Infarction Postconditioned with Lactate-Enriched Blood
Takashi Koyama1, Masahito Munakata2, Takashi Akima2
1Department of Cardiology, Saitama Municipal Hospital, Saitama, Japan, koyamas@me.com.
Insights
Postconditioning with lactate-enriched blood (PCLeB) significantly reduced NT-proBNP levels months after myocardial infarction (MI). This cardioprotective approach shows promise for improving long-term outcomes in STEMI patients.
Area of Science:
- Cardiology
- Cardiovascular Research
- Regenerative Medicine
Background:
- ST-segment elevation myocardial infarction (STEMI) requires effective cardioprotective strategies.
- Postconditioning with lactate-enriched blood (PCLeB) is a novel approach for myocardial protection.
- Evaluating long-term biomarker changes post-MI is crucial for assessing treatment efficacy.
Discussion:
- This study investigated the impact of PCLeB on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.
- NT-proBNP is a key biomarker for heart failure and cardiac strain.
- Comparing post-MI NT-proBNP levels between PCLeB-treated and control groups provides insights into treatment effectiveness.
Key Insights:
- PCLeB treatment was associated with significantly lower plasma NT-proBNP levels months after myocardial infarction (MI).
- Patients receiving PCLeB showed mean NT-proBNP levels of 211 ± 207 pg/mL compared to 516 ± 598 pg/mL in controls (p < 0.0001).
- These findings suggest PCLeB may mitigate long-term cardiac remodeling or dysfunction post-STEMI.
Outlook:
- Further research is warranted to elucidate the precise mechanisms underlying PCLeB's cardioprotective effects.
- Investigating the long-term clinical outcomes and potential benefits of PCLeB in larger STEMI cohorts is recommended.
- PCLeB could represent a valuable therapeutic option for improving myocardial recovery and reducing heart failure risk after MI.
Background:
We recently reported a new approach, namely postconditioning with lactate-enriched blood (PCLeB), for cardioprotection in patients with ST-segment elevation myocardial infarction (STEMI).
Objectives:
We examined the effects of PCLeB on plasma NT-proBNP levels months after myocardial infarction (MI).
Methods:
The study included consecutive patients (n = 31) undergoing percutaneous coronary intervention (PCI) for anterior STEMI within 12 h of symptom onset in our hospital between March 2014 and August 2018. We retrospectively compared plasma NT-proBNP levels several months after MI in these patients with those in historical control patients (n = 32). The control patients included consecutive patients who underwent successful PCI without PCLeB for anterior STEMI within 12 h of symptom onset in our hospital between March 2009 and February 2014. We compared the highest plasma NT-proBNP values 6-10 months after MI in the postconditioned patients with the lowest plasma NT-proBNP values 6-10 months after MI in the control patients. In the PCLeB protocol, the duration of each brief reperfusion was increased stepwise from 10 to 60 s. Lactated Ringer's solution (30 mL) was injected directly in the culprit coronary artery at the end of each brief reperfusion. Each ischemic episode lasted 60 s.
Results:
Plasma NT-proBNP levels in the postconditioned patients months after MI (211 ± 207 pg/mL) were significantly lower than those in the control patients (516 ± 598 pg/mL; p < 0.0001).
Conclusion:
PCLeB was associated with reduced plasma NT-proBNP levels months after MI.
More Related Videos
10:01Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018
11:07A Murine Model of Myocardial Ischemia-reperfusion Injury through Ligation of the Left Anterior Descending Artery
Published on: April 10, 2014
